Accord’s goal of commercializing 20 US biosimilars by 2030 is a step closer with the latest biosimilar launch of Filkri ...

Patient-generated data and real-world data could help shore up the evidence base of innovative products that have been ...

Biosimilar bets are forecasts built on a forecast: estimate the originator's value at LOE a decade out, while the molecule is ...

Biosimilar developers must value someone else's molecule a decade out, then forecast their own share of it. Currently the ...

Dsm-firmenich’s Carl D’Ruiz explains during an Oct. 14 webinar how BEMT is enabling US formulators to make more creative and ...

CMS is eager to work with Congress to control premium growth in Part D once the existing 6% cap on the base beneficiary ...

Brent Saunders apparently wasn’t a cog in B+L’s confidence in expecting to increase its full-year guidance. Canadian firm ...

Barry Chaiken says AI chatbots are eroding guided self-care and that the industry, rather than tech companies, should set ...

Third quarter data from Evaluate show nine biopharma initial public offerings on Western exchanges totaling $2.39bn. Average ...

Phase I/IIa data for the siRNA drug showed it can cross the blood-brain barrier when administered via subcutaneous injection, ...

The FDA’s cross-agency initiative to build a fit-for-purpose framework would expand reviewer engagement with external experts ...

The MedTech Conference, hosted by AdvaMed, will bring more than 4,000 industry leaders to Boston Oct. 18–21 to discuss major ...